Daily FNArena News - Small Caps

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports

The New Criterion’s Tim Boreham navigates the choppy seas of a fraught Australian seafood-farming market

While interim results for Sigma Healthcare met expectations, brokers see margin upside from improved operating leverage

Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030

Brokers are excited about the growth prospects of rural transport and logistics company Lindsay Australia as it becomes the number one player in its industry

Tim Boreham highlights a device used to detect pain in non-verbal patients, such as those suffering dementia and infants

Tim Boreham shines a light on freshly listed Cleo Diagnostics, in search of an effective diagnostic tool for ovarian cancer

Let’s talk about the unbreakable bond between households and their pets, and about the companies that offer exposure. Updated with today’s FY23 result release

Australia is the first country in the world to legalise the use of psychedelic drugs for mental illness

Temple & Webster seems destined for strong growth, but at a lower margin as spending increases to grab more market share